|
Title
|
Published
|
Price
|
|
The PI3K/Akt/mTOR Pathway
By: CHI Insight Pharma Reports
... This report includes: Pipeline reviews of PI3K, Akt, mTOR, and dual kinase inhibitors in development and an assessment of the current prospects for each approach Role of the PI3K/Akt/mTOR cascade in various diseases and potential ...
|
more...
|
11/1/2011
|
$2,495.00
|
|
New Trends in Preventive and Therapeutic Vaccines
By: CHI Insight Pharma Reports
... tropical viruses, and HIV Therapeutic vaccines that target HIV, HCV, asthma and allergy, type 1 diabetes, multiple sclerosis, psoriasis, arthritis, atherosclerosis, transplant rejection, Alzheimer's disease, periodontitis, substance abuse, obesity, cachexia, and age-related macular degeneration Therapeutic ...
|
more...
|
10/1/2011
|
$2,495.00
|
|
Cytokine-Based Therapies and Inhibitors:R&D Pipelines, Markets, and Strategic Issues
By: CHI Insight Pharma Reports
... or inhibit cytokines and/or cytokine receptors. This report examines: Marketed cytokine-based therapies and inhibitors, and emerging new therapies Activities to expand approved indications for cytokines and cytokine inhibitors Pipeline of cytokine therapies and inhibitors in ...
|
more...
|
9/1/2011
|
$2,495.00
|
|
Kinase-Targeted Therapeutics: Development Pipelines, Challenges, and Opportunities
By: CHI Insight Pharma Reports
... clinical evaluation. Kinases make up a veritable treasure trove of targets for a variety of indications. This report analyzes: The considerable array of therapeutic development efforts directed at kinases Current and emerging technologies being applied ...
|
more...
|
8/1/2011
|
$595.00
|
|
Next-Generation Mass Spectrometry: Technology Advances and Applications
By: CHI Insight Pharma Reports
... of data in the medical sciences that brings new insights into critical questions. This report analyzes: Physical principles and analytical applications of mass spectrometry The role of mass spectrometry in genomics, proteomics, metabolomics, and lipidomics ...
|
more...
|
7/1/2011
|
$595.00
|
|
Engineering Next-Generation Therapeutic Proteins: Trends and Markets To 2020
By: CHI Insight Pharma Reports
... protein engineering and developments that are likely to occur through 2020. Contents include: State of the current technology and where the immediate development vectors are pointing Current efforts to engineer developability into protein drug candidates ...
|
more...
|
7/1/2011
|
$3,195.00
|
|
Multitargeted Therapies
By: CHI Insight Pharma Reports
... are promiscuous, i.e., they are single drugs that address multiple targets. This report covers both these major approaches to development of multitargeted therapies. Discussed are: The discovery and design of promiscuous drugs The rational design ...
|
more...
|
6/1/2011
|
$3,195.00
|
|
Next Generation Sequencing Generates Momentum
By: CHI Insight Pharma Reports
... new scaled-down instruments to broaden the market? What Generation 2.5 systems featuring new detection technologies and single-molecule sequencing are now on the market? When will third generation of instruments led by nanopore technologies be entering ...
|
more...
|
6/1/2011
|
$3,195.00
|
|
Autoimmune Diseases: Pipelines for Crohn's Disease, Multiple Sclerosis and Rheumatoid Arthritis
By: CHI Insight Pharma Reports
... targets are actively being investigated and what new targets are coming forward? Who has candidates in active Phase III and Phase II clinical trials? What does the overall target activity map, from launched drug to ...
|
more...
|
6/1/2011
|
$795.00
|
|
Commercializing Biomarkers in Therapeutic and Diagnostic Applications
By: CHI Insight Pharma Reports
... about biomarkers and successfully commercialize them in therapeutic and diagnostic applications. Included in this publication: Biomarker definitions and guidelines for their development and validation Applications of biomarkers in oncology, cardiology, neurology, drug safety, and other ...
|
more...
|
5/1/2011
|
$3,195.00
|
|
Monoclonal Antibodies: A Segment of Major Growth
By: CHI Insight Pharma Reports
... and are poised to continue growing steadily through to 2015. Discussed in this report: Nearly 300 monoclonal antibodies currently in clinical development, organized by indication and/or target Sales of currently marketed monoclonal antibodies, market share ...
|
more...
|
3/1/2011
|
$3,195.00
|
|
Molecular Diagnostics: Double-Digit Growth Anticipated
By: CHI Insight Pharma Reports
... (POC) products, the appearance of sequencing-based assays that could fundamentally alter the field and automated low-density microarray-based assays. Discussed in this report: The technological landscape underlying molecular diagnostics today Products and systems currently on the ...
|
more...
Search inside this report
|
2/1/2011
|
$3,195.00
|
|
Partnering Terms and Agreements in Diagnostics , 2nd edition
By: CHI Insight Pharma Reports
... documents Diagnostic agreement terms Diagnostic agreement structure Top diagnostic deals by value Most active diagnostic dealmakers Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms ...
|
more...
|
11/10/2010
|
$2,695.00
|
|
Distribution Partnering Terms and Agreements in Pharma, Biotech and Diagnostics, 3rd edition
By: CHI Insight Pharma Reports
... detailed understand and analysis of how and why companies enter distribution deals. The majority of deals are multicomponent whereby the licensor offers a right to distribute the resultant product of the research collaboration. There are ...
|
more...
|
10/1/2010
|
$2,695.00
|
|
Diabetes Pipeline: Intense Activity to Meet Unmet Need Report
By: CHI Insight Pharma Reports
... agents provide imperfect control of the disease, and the medical need for better therapies is widely recognized. This report discusses: Pros and cons of marketed therapies and snapshots of the global diabetes market Development pipelines ...
|
more...
|
9/1/2010
|
$2,995.00
|
|
Therapeutic Monoclonal Antibody Production
By: CHI Insight Pharma Reports
... economically complex monoclonal antibody molecules. While most antibody biologics are anti-cancer agents, there are a number of other areas of disease management to which biologics in this class are starting to play a significant role. ...
|
more...
|
7/1/2010
|
$2,995.00
|
|
Therapeutic Protein Production: A Changing Landscape
By: CHI Insight Pharma Reports
... disposables throughout the process and the shift to animal extracts-free culture media are three of the major themes covered by this report. The impact of global competition, lower barriers to entry and the shift in ...
|
more...
Search inside this report
|
7/1/2010
|
$3,750.00
|
|
Drug Repositioning
By: CHI Insight Pharma Reports
... trials (for reasons other than safety) for potential use in other therapeutic indications. Discussed in this Report: Intellectual property coverage for new uses of known drugs Tool sets for identifying repositioning opportunities and business strategies ...
|
more...
|
7/1/2010
|
$2,995.00
|
|
Epigenetic Drug & Diagnostic Pipelines: DNA Methylation, HDAC Inhibitors, and Emerging New Targets Report
By: CHI Insight Pharma Reports
... of discoveries in this field. Discussed in this Report: Diagnostic applications of epigenetics Diseases and conditions targeted by current and emerging epigenetic-based therapies Companies marketing and/or developing therapies that target epigenetic changes within the disease ...
|
more...
|
6/1/2010
|
$2,995.00
|
|
Epigenetic Drug & Diagnostic Pipelines
By: CHI Insight Pharma Reports
... commercialization of discoveries in this field. Discussed in this Report: Diagnostic applications of epigenetics Diseases and conditions targeted by current and emerging epigenetic-based therapies Companies marketing and/or developing therapies that target epigenetic changes within the ...
|
more...
|
5/1/2010
|
$3,750.00
|
|
Combination Drug/Diagnostic Products and Other Applications of Personalized Medicine-Strategic Issues Facing Companies in this Market
By: CHI Insight Pharma Reports
... Personalized medicine has emerged as an important field for companies in both the pharmaceutical and the diagnostic industries. While many drugs in development and on the market today still follow the traditional approach where drugs ...
|
more...
|
4/1/2010
|
$2,995.00
|
|
Cloud Computing in Life Sciences R&D Report
By: CHI Insight Pharma Reports
... of companies that are active in the field Current and emerging applications of cloud computing, with special emphasis on next-generation sequencing and its resultant data Market aspects of cloud computing, including competition among providers and ...
|
more...
|
4/1/2010
|
$2,995.00
|
|
Combination Drug Diagnostics: Fueling Growth of Personalized Medicine Report
By: CHI Insight Pharma Reports
... combinations Emerging new applications Strategic options for pharmaceutical and diagnostic companies Regulatory and reimbursement issues Physician education and acceptable hurdles Interviews with experts Combination Drug/Diagnostics: Fueling Growth of Personalized Medicine examines the role of Rx/Dx ...
|
more...
|
4/1/2010
|
$3,750.00
|
|
Animal Models for Therapeutic Strategies
By: CHI Insight Pharma Reports
... Case studies of the use of established animal models in developing novel therapeutic strategies Emerging animal models for use in drug discovery and the development of new therapeutic strategies Development of animal models that are ...
|
more...
|
3/1/2010
|
$2,995.00
|
|
Strategic Alliances: Synergistic Path To Value Creation
By: CHI Insight Pharma Reports
... and the stagnant productivity of R&D. As a consequence generics are expected to seriously erode revenues and the introduction of new proprietary drugs is not adequate. The once insular pharmaceutical industry has been forced to ...
|
more...
|
1/1/2010
|
$2,995.00
|
|
Title
|
Published
|
Price
|
(0 items)
